HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): William L. Holman Edward R. Ferguson David C. McGiffin James K. Kirklin Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holman, W. L. Articles by Kirklin, J. K. Search for Related Content PubMed PubMed Citation Articles by Holman, W. L. Articles by Kirklin, J. K.

Ann Thorac Surg 1996;61:366-371
© 1996 The Society of Thoracic Surgeons

---

Infection

Infections During Extended Circulatory Support: University of Alabama at Birmingham Experience 1989 to 1994

Departments of Cardiothoracic Surgery and Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama

Abstract

Background. The University of Alabama at Birmingham experience with investigational ventricular assist devices (VADs) used as a bridge to transplantation has increased over the past several years; it now includes 27 VAD implantations with 13 VAD runs lasting for extended periods (ie, >30 days). A review of complications experienced by patients during extended VAD runs is warranted before the further development and testing of chronically implanted mechanical circulatory support devices.

Methods. This study focuses on the infectious complications of extended VAD support; it includes 13 patients who were supported by either a Thoratec or HeartMate VAD for longer than 30 days pending cardiac transplantation. Infection was defined as any positive culture. The infections were classed according to site and severity as class I were patient-related non-blood-borne infections, class II were blood-borne infections, class III were VAD percutaneous site infections, and class IV were infections of the blood-contacting surfaces or intracorporeal components of the VAD.

Results. The 8 Thoratec and 5 HeartMate patients were supported for a total of 1,648 days with a range of 33 to 279 days per patient. Every patient had at least one infection; however, there were 6 patients who had no class II or IV infections during the period of support. One of these 6 patients died of a stroke, whereas the other 5 patients survived VAD support. No trends were identified for a change in the incidence of bacterial compared with fungal infections during the course of VAD support. There was no trend for a greater number of infections in patients who died during VAD support compared with those who survived. Neither class II nor IV infections precluded transplantation. Three patients died during VAD support; 1 died as a direct consequence of fungal infection. Eight patients received transplants. One patient had an unanticipated recovery of cardiac function and the VAD was removed. Support in 1 patient is ongoing.

Conclusions. Infection during VAD support pending cardiac transplantation is an important cause of morbidity and mortality in patients maintained for longer than 30 days by circulatory assist. Infectious complications will probably be a prominent component of the risk associated with the use of chronically implanted mechanical circulatory assist devices and will likely have an important effect on the quality of life experienced by these patients.

This article has been cited by other articles:

				J. O. Robertson, C. Lober, N. G. Smedira, J. L. Navia, N. Sopko, and G. V. Gonzalez-Stawinski One hundred days or more bridged on a ventricular assist device and effects on outcomes following heart transplantation. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 295 - 300. [Abstract] [Full Text] [PDF]

				T. Asai, M.-H. Lee, C. Arrecubieta, M. P. von Bayern, C. A. Cespedes, H. M. Baron, M. Cadeiras, T. Sakaguchi, C. C. Marboe, Y. Naka, et al. Cellular coating of the left ventricular assist device textured polyurethane membrane reduces adhesion of Staphylococcus aureus J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1147 - 1153. [Abstract] [Full Text] [PDF]

				R. A. Vilchez, M. C. McEllistrem, L. H. Harrison, K. R. McCurry, R. L. Kormos, and S. Kusne Relapsing bacteremia in patients with ventricular assist device: an emergent complication of extended circulatory support Ann. Thorac. Surg., July 1, 2001; 72(1): 96 - 101. [Abstract] [Full Text] [PDF]

				W. L. Holman, R. J. Fix, B. A. Foley, D. C. McGiffin, B. K. Rayburn, and J. K. Kirklin Management of wound and left ventricular assist device pocket infection Ann. Thorac. Surg., September 1, 1999; 68(3): 1080 - 1082. [Abstract] [Full Text] [PDF]

				D. G. Pennington, T. E. Oaks, and D. P. Lohmann Permanent ventricular assist device support versus cardiac transplantation Ann. Thorac. Surg., August 1, 1999; 68(2): 729 - 733. [Abstract] [Full Text] [PDF]

				S. H. McKellar, B. D. Allred, J. D. Marks, C. G. Cowley, D. C. Classen, S. C. Gardner, and J. W. Long Treatment of infected left ventricular assist device using antibiotic-impregnated beads Ann. Thorac. Surg., February 1, 1999; 67(2): 554 - 555. [Abstract] [Full Text] [PDF]

				S. A. Hunt and O.H. Frazier Mechanical Circulatory Support and Cardiac Transplantation Circulation, May 26, 1998; 97(20): 2079 - 2090. [Full Text] [PDF]